|
1
|
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
|
Lancet
|
2014
|
9.66
|
|
2
|
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
|
J Clin Oncol
|
2012
|
8.74
|
|
3
|
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
|
N Engl J Med
|
2014
|
6.76
|
|
4
|
Adjuvant ovarian suppression in premenopausal breast cancer.
|
N Engl J Med
|
2014
|
5.18
|
|
5
|
Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.
|
J Natl Cancer Inst
|
2005
|
4.48
|
|
6
|
-Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.
|
Ann Oncol
|
2015
|
4.31
|
|
7
|
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.
|
J Clin Oncol
|
2011
|
2.71
|
|
8
|
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
|
Lancet Oncol
|
2012
|
2.25
|
|
9
|
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
|
Cancer
|
2007
|
1.53
|